Avalon GloboCare Corporation - רווח נקי למניה (EPS TTM) ALBT

Avalon GloboCare's stable image in test distribution guarantees business resilience, as evidenced by the current YoY TTM growth in net income per share, where the figure remains around 75.10. The company's foundation is based on a closed medical ecosystem spanning from screening to treatment. Additional potential is created by biotechnological developments in the field of personalized oncology therapy.
ALBT (Avalon GloboCare Corporation): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Effective diversification of biomedical supply chains at Avalon GloboCare (ALBT) directly impacts margins, as reflected in the change in EPS YoY on a rolling 12-month basis. This indicator compares net earnings per share for the current year with the same prior period, allowing investors to assess the sustainability of the profitability trend and the real dynamics of business capitalization while filtering out short-term market noise.